Comment from Anonymous

Informational Briefing Submitted for the Record to the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) Date: June 1, 2026 Docket No: FDA-2026-N-4162 Subject: Technical Briefing on Official Preclinical Biodistribution Data Regarding Ovarian Accumulation of Lipid Nanoparticle (LNP) Formulations. Meeting Context: June 18, 2026, Open Session Review of Biologics License Application (BLA) STN 125869/0 for MFLUSIVA (Influenza Vaccine, mRNA), manufactured by Moderna TX Inc. 1. Verified Regulatory Grounding: Preclinical Ovarian Biodistribution To ensure absolute scientific utility to the Committee, this briefing is restricted exclusively to verified data derived from official regulatory application dossiers, nonclinical evaluation reports, and established pharmacokinetic principles reviewed by global regulatory authorities (including the FDA and EMA). The foundational factor under evaluation is the non-localized distribution of the lipid nanoparticle vehicle independently of its antigenic payload: Quantifiable Ovarian Concentration: Official regulatory nonclinical biodistribution dossiers utilizing radiolabeled (3H) lipid nanoparticles or surrogate mRNA-LNP constructs demonstrate that upon intramuscular or intravenous injection, the four-component lipid vehicle does not remain entirely localized to the site of injection or the surrounding draining lymph nodes. Pharmacokinetic Clearance Curves: Preclinical animal models submitted within platform dossiers establish that a measurable percentage of the total administered lipid dose distributes systemically via the bloodstream. While the highest concentrations outside the injection site are consistently observed in the liver, spleen, and adrenal glands, a reproducible distribution curve moves into ovarian tissues, where concentrations increase over the first 48 hours post-administration. The Blood-Follicle Barrier Variable: Regulatory evaluation reports (e.g., EMA/422204/2021) document that synthetic ionizable lipids and structural helper lipids cross the blood-follicle barrier during the vascular perfusion phase. This establishes a verifiable tissue-retention footprint within the reproductive organs during the acute pharmacokinetic window. 2. Definitive Regulatory Citations The committee is directed to the following specific nonclinical dossiers and harmonized framework parameters that record these tissue distribution dynamics: European Medicines Agency Assessment Dossier: EMA/422204/2021 (Section 2.3.2: Pharmacokinetics / Biodistribution). Formally documents the explicit tissue distribution data of ionizable lipid nanocarriers, explicitly detailing the milligram-equivalent concentration curves tracking into ovarian tissues over a 48-hour observation timeline. Therapeutic Goods Administration (TGA) Nonclinical Evaluation: Submission No: PM-2020-05461-1-2 (Section 2.2: Pharmacokinetics). Official regulatory review of platform lipid tracking (3H-cholesteryl hexadecyl ether) demonstrating systematic systemic escape from lymphoid tissue and subsequent distribution into the female reproductive organs. FDA Nonclinical Framework Standards: FDA Guidance for Industry / ICH S5(R3) (Guidance on Reproductive Toxicity and Biodistribution Testing). Establishes the regulatory baseline that when a delivery platform's structural components demonstrate non-localized tissue-specific accumulation (such as ovarian tracking), high-resolution pharmacokinetic resolution of the target organs is a standard element of safety profile verification.